The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities

Daniel Vázquez(Diagnostico Maipú), Nihal Mete Gökmen(Ege University), Darío Josviack, Hiroshi Chantaphakul(King Chulalongkorn Memorial Hospital), Erminia Giordano(University of Naples Federico II), J. Bernstein(University of Cincinnati), Mohammad Reza Fazlollahi(Tehran University of Medical Sciences), Hilary D. Andoh(Ghana Health Service), Giorgio Walter Canonica(Humanitas University), Manuel Branco Ferreira(Hospital de Santa Maria), Marcelo Vívolo Aun(Hospital Israelita Albert Einstein), Aleena Banerji(Massachusetts General Hospital), Kassim Babu Mapondela(Muhimbili National Hospital), Mary Beth Fasano(Atrium Health Wake Forest Baptist), Claudio Fantini, Allen P. Kaplan(Medical University of South Carolina), Motohiro Ebisawa(National Sagamihara Hospital), Alessandro Fiocchi, Jose Luis García Abujeta(Hospital Universitari Sant Joan D'Alacant), Raúl Castro Almarales(Hospital Oncológico Docente "Conrado Benítez García"), Noémi‐Anna Bara, Olga Melcina Barrera(Saint Thomas Hospital), Fátima Rodrigues Fernandes(Hospital do Servidor Público Estadual), Tinatin Chikovani, Nancy Agmon‐Levin(Sheba Medical Center), Y. J. Chang(Seoul National University), Pedro Giavina-Bianchi(Universidade de São Paulo), Ines Allam(University of Algiers Benyoucef Benkhedda), Francisco Alberto Contreras-Verduzco(Instituto Nacional de Pediatria), S. Altrichter(Johannes Kepler University of Linz), R. Mohammed Ali(Hamad Medical Corporation), Mona Al-Ahmad(Kuwait University), Herberto Jose Chong-Neto(Universidade Federal do Paraná), Sultan Alandijani(King Faisal Specialist Hospital & Research Centre), Claudia Gallego(Universidad Autónoma de Nuevo León), Lorenzo Cecchi(Nuovo Ospedale San Giovanni di Dio), Zeinab A. El-Sayed(Ain Shams University), Maryam Al-Nesf Al-Mansouri(Hamad Medical Corporation), Paulo Barrera Perigault(Saint Thomas Hospital), Oscar Manuel Calderón-Llosa(Universidad de San Martín de Porres), Euguens Femine(Liberty University), José Enrique Gereda(Universidad Ricardo Palma), Shahid Abbas(American University in Dubai), Salem Al-Tamemi(Sultan Qaboos University Hospital), Vilbrun Dorsainvil(Liberty University), Mirta Álvarez Castelló(Hospital Oncológico Docente "Conrado Benítez García"), Pablo A.S. Martinez(Universidad Nacional del Sur), Luz Fonacier(Long Island University), Hani Abdullah Alhashmi(King Abdulaziz Hospital), Federica Defendi(Centre Hospitalier Universitaire de Grenoble)
World Allergy Organization Journal
March 19, 2026
10.1016/j.waojou.2026.101335
Cited by 4

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
World Allergy Organization Anaphylaxis Guidance 2020
|World Allergy Organization Journal|2020|1.1k